glp 1 and low blood sugar GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes GLP-1 Agonists - What is

Among these, 21 are focused on weight loss and 14 on type II diabetes

As the use of GLP-1 medications expands, a growing number of individuals report gastrointestinal side effects such as delayed gastric emptying, nausea, and broader shifts in digestive function

The SUSTAIN-6 trial, which evaluated semaglutide in patients with type 2 diabetes at high cardiovascular risk, identified a statistically significant increase in diabetic retinopathy complications in the semaglutide group compared to placebo

Wegovy oral (semaglutide pill) , FDA-approved for weight loss in late 2025 and launched January 2026, runs $149$299/mo through manufacturer direct programs and select telehealth routes

Pfeifer KJ, Selzer A, Mendez CE, et al

A more aggressive approach would be to require a routine step through SGLT2s or DPP-4s to access GLP-1s, which clinicians on the panel said lacked clinical nuance